Isomorphic Labs has turned AI drug discovery into a 2.1B capital story – Startup Fortune

AI Briefing
5 most important AI updates after 8pm every day, curated for you.
Isomorphic Labs has raised 2.1 billion in Series B funding, a sign that investors are backing AI drug discovery with infrastructure-scale capital rather than small biotech-style bets.
Isomorphic Labs has raised 2.1 billion in fresh capital, and the size of the round says as much about investor conviction as it does about the company’s science.
The Alphabet-backed drug discovery company, led by Demis Hassabis, disclosed the Series B on May 12, saying the money will power its AI drug design engine, widen its global footprint, and push its pipeline toward the clinic, according to the company and Reuters. The round was led by Thrive Capital and also included Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.
That matters because this is no longer just a story about promising models and lab demos. It is a capital-intensive bet that AI can change one of the slowest, most expensive industries on earth, and that the companies closest to the frontier will need billions, not millions, to prove it.
Isomorphic’s own announcement makes the scale clear. The company said the Series B brings in 2.1 billion to support its AI drug design engine, known as IsoDDE, and to progress drug candidates across several therapeutic areas and modalities. Reuters reported that the round closed at an undisclosed valuation, while noting that the company has not yet disclosed the number publicly.
Even without a valuation, the message from the investor roster is hard to miss. This is a coalition of long-horizon capital, with existing backers doubling down and new investors stepping in at a moment when the market is still sorting out which AI-biotech names can turn computational promise into approved medicines. For a sector where many companies raise on platform potential, the size of this round suggests that Isomorphic is being priced as infrastructure for drug discovery, not just a single-asset biotech.
It also builds on a prior raise. Reuters and other outlets reported that Isomorphic closed a 600 million round in March 2025, meaning the company has now pulled in roughly 2.7 billion in outside capital across two rounds. That is an unusually large war chest for a company still working its way toward its first clinical trials.
The appeal is straightforward. Traditional drug development takes years, often decades, and comes with a punishing failure rate. Isomorphic is trying to compress that process by using AI to predict molecular behavior earlier, narrow the search space, and design candidates with a better shot of working before expensive wet-lab and clinical work begins.
Hassabis has framed the company’s mission in unusually sweeping terms. Reuters quoted him saying the new funding lets Isomorphic build out its drug design engine at scale and move forward in its mission to “solve all disease,” language that also appeared in the company’s own announcement. That kind of ambition is easy to dismiss until it is backed by serious institutional money, and this round does exactly that.
The broader market context helps explain the timing. Reuters reported in January that investors were anticipating a rebound in biotech dealmaking in 2026, with renewed interest in companies that can show credible progress toward the clinic. AI-biotech sits right at the intersection of two themes investors still like: software-style leverage and life sciences upside. If the models work, the payoff could be huge. If they do not, the burn rate will punish even deep-pocketed players.
Isomorphic is not operating in a vacuum. The field includes public names such as Recursion and private challengers like Xaira and others chasing the same broad thesis, that machine learning can make biology more legible and drug discovery more efficient. What separates Isomorphic at the moment is not just the pedigree of its parent company and founder, but the scale of the financing it can command before any commercial product is on the market.
That scale changes the competitive map. Smaller AI-drug discovery firms may still have strong platforms, but they now have to compete against a company that can fund multiple programs, hire aggressively, and wait longer for proof. In biotech, patience is often a luxury. In this case, it is part of the strategy.
There is also a geographic signal here. The round brought together capital from the U.S., the Gulf, Europe, and Southeast Asia, which tells you that AI in life sciences is no longer being treated as a niche venture bet in one market. It is becoming a global allocation theme, much like cloud infrastructure or foundation-model stacks did earlier in the AI cycle.
For readers tracking where the next wave of AI capital is going, that is the real story. Isomorphic Labs is not only raising money to build drugs. It is helping define the size of the market for AI-native biotech itself, and investors just handed it one of the biggest checks in the sector so far.
Also read: OpenAI’s ad push could finally put Google’s core search ads at risk • CXMT’s IPO could test how far China’s memory chip ambitions have come • Byju Raveendran’s Singapore jail term deepens the lesson on founder accountability

source